Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

This clinical trial aims to investigate the effectiveness and safety of a new treatment combination-Iparomlimab and Tuvonralimab (QL1706, a dual-function antibody targeting PD-1 and CTLA-4) combined with chemotherapy-for patients with malignant mesothelioma (MM). MM is a rare and aggressive cancer often linked to asbestos exposure. Current treatments have limited success, and this study seeks to explore a potentially more effective and safer option. Study Design: Phase Ib (Safety Phase): 6 patients will receive the combination therapy to assess safety. If no major safety issues arise, the study will proceed to Phase II. Phase II (Efficacy Phase): 49 patients will be enrolled to evaluate treatment effectiveness. The study includes two groups for first-line treatment and second-line treatment.

NCT Number	NCT07131345
Lead Sponsor	National Cancer Center, China Collaborators: Qilu Pharmaceutical Co., Ltd., Affiliated Cancer Hospital of Zhengzhou University, Beijing Chest Hospital, Capital Medical University, The Affiliated Hospital of Inner Mongolia Medical University, Shaanxi Provincial Cancer Hospital
Conditions	Malignant Mesothelioma, Mesothelioma
Enrollment	55 participants
Start Date	2025-09-01
Primary Completion	2026-10-31 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-20